An observational study in Nut Hypersensitivity, Child and Legumes Allergy, sponsored by Lille Catholic University. Completed. Per ClinicalTrials.gov, last updated 2016-11-11.
Sponsored by Lille Catholic University · Observational
Peanut allergy (PA) has been well studied and its prevalence was estimated up to 1.3% in Europe. Tree nut (TN) allergy and PA are clinically similar and often coexist, TN allergy prevalence ranged from 0.05 to 4.9 %. TN allergy is longlasting and nearly all TN have been associated with fatal allergic reactions . Other legumes or TN also contain seed storage protein orthologs of the globulins (Ara h1, Ara h 3) and 2S albumins (Ara h 2) of peanut, susceptible to provoke allergic reactions, but cross-reactivity to TN and other legumes in PA patients could also appear through primarily sensitization. These possible IgE-binding cross-reactions bring to recommend the avoidance of TN and other legumes which have never been eaten in PA children. In this context, diagnosis work-up of relevant cross-allergy versus asymptomatic cross-sensitization will impact directly children's health-related quality of life (HRQL).
When physicians suspect food allergy, many parameters have to be considered, such as clinical background, clinical history, type of symptoms related to the suspected food and cross-allergy to other foods. Then, to objectively confirm a food allergy and to assess its severity (related to the threshold reactive dose and symptoms), an oral food challenge (OFC) is demanded, and double-blind placebo-controlled food challenge (DBPCFC) is considered as "the gold standard".
Although OFC are more and more available in the diagnosis of PA, the assessment of cross-allergy to every single allergenic TN and legumes requires full allergy work-up and often many years of follow-up. Few studies investigated cross-allergy to TN and other legume, with rates of cross-allergy to TN between 28% and 50%. However, targeting patients with severe or cross-allergic phenotypes would greatly assist the allergist in management and follow-up of PA patients (i.e., planning OFC to cross-reactive food).
Our main objective is to identify different disease phenotypes of PA children with cluster analysis. This statistical approach has never been performed to identify cross-allergic phenotypes. We also will describe cross-allergy in PA and will identify possible risk factors for cross-allergy to TN and other legumes in PA children.
33 studies on the registry are indexed under Nut Hypersensitivity; 9 are open to participants now.
This study's enrollment of 317 is above the median of 240 across 11 observational studies indexed under Nut Hypersensitivity.
Browse Nut Hypersensitivity studies →Lille Catholic University is the lead sponsor of 112 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Children with peanut allergy who had a complete evaluation about cross-allergy to Tree Nuts and other legumes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Cross reaction detection
Double-blind placebo-controlled food challenge Test for determination of type of allergic reaction
After the test (DBPCFC) the type of allergic reaction will be registered: asthma and allergic rhinitis (AR)
Time frame: at inclusion
Double-blind placebo-controlled food challenge Test for determination of threshold reactive dose
Time frame: at inclusion
Measure of specific IgEs for the peanut component Ara h 1, Ara h 2, Ara h 3
Time frame: at inclusion
Oral food challenge test for diagnosis of tree nuts and/or other legumes allergies
Time frame: through the study completion
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.